Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors

Yuji Ikari; Yuya Matsue; Sho Torii; Misaki Hasegawa; Kazuki Aihara; Shunsuke Kuroda; Takahide Sano; Takeshi Kitai; Taishi Yonetsu; Shun Kohsaka; Takuya Kishi; Issei Komuro; Ken Ichi Hirata; Koichi Node; Shingo Matsumoto

doi:10.1253/circj.CJ-21-0087

Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors

Yuji Ikari, Yuya Matsue, Sho Torii, Misaki Hasegawa, Kazuki Aihara, Shunsuke Kuroda, Takahide Sano, Takeshi Kitai, Taishi Yonetsu, Shun Kohsaka, Takuya Kishi, Issei Komuro, Ken Ichi Hirata, Koichi Node, Shingo Matsumoto

Department of Internal Medicine (Cardiology)

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19). Methods and Results: In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus. Conclusions: This study suggests the potential benefits of statins use against COVID-19.

Original language	English
Pages (from-to)	939-943
Number of pages	5
Journal	Circulation Journal
Volume	85
Issue number	6
DOIs	https://doi.org/10.1253/circj.CJ-21-0087
Publication status	Published - 2021

Keywords

Cardiovascular risk factors
Coronavirus disease 2019 (COVID-19)
Statin

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1253/circj.CJ-21-0087

Cite this

Ikari, Y., Matsue, Y., Torii, S., Hasegawa, M., Aihara, K., Kuroda, S., Sano, T., Kitai, T., Yonetsu, T., Kohsaka, S., Kishi, T., Komuro, I., Hirata, K. I., Node, K., & Matsumoto, S. (2021). Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors. Circulation Journal, 85(6), 939-943. https://doi.org/10.1253/circj.CJ-21-0087

Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors. / Ikari, Yuji; Matsue, Yuya; Torii, Sho; Hasegawa, Misaki; Aihara, Kazuki; Kuroda, Shunsuke; Sano, Takahide; Kitai, Takeshi; Yonetsu, Taishi; Kohsaka, Shun; Kishi, Takuya; Komuro, Issei; Hirata, Ken Ichi; Node, Koichi; Matsumoto, Shingo.

In: Circulation Journal, Vol. 85, No. 6, 2021, p. 939-943.

Research output: Contribution to journal › Article › peer-review

Ikari, Y, Matsue, Y, Torii, S, Hasegawa, M, Aihara, K, Kuroda, S, Sano, T, Kitai, T, Yonetsu, T, Kohsaka, S, Kishi, T, Komuro, I, Hirata, KI, Node, K & Matsumoto, S 2021, 'Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors', Circulation Journal, vol. 85, no. 6, pp. 939-943. https://doi.org/10.1253/circj.CJ-21-0087

Ikari, Yuji ; Matsue, Yuya ; Torii, Sho ; Hasegawa, Misaki ; Aihara, Kazuki ; Kuroda, Shunsuke ; Sano, Takahide ; Kitai, Takeshi ; Yonetsu, Taishi ; Kohsaka, Shun ; Kishi, Takuya ; Komuro, Issei ; Hirata, Ken Ichi ; Node, Koichi ; Matsumoto, Shingo. / Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors. In: Circulation Journal. 2021 ; Vol. 85, No. 6. pp. 939-943.

@article{556e231ba7974f66b9cf3e74b76662da,

title = "Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors",

abstract = "Background: Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19). Methods and Results: In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus. Conclusions: This study suggests the potential benefits of statins use against COVID-19.",

keywords = "Cardiovascular risk factors, Coronavirus disease 2019 (COVID-19), Statin",

author = "Yuji Ikari and Yuya Matsue and Sho Torii and Misaki Hasegawa and Kazuki Aihara and Shunsuke Kuroda and Takahide Sano and Takeshi Kitai and Taishi Yonetsu and Shun Kohsaka and Takuya Kishi and Issei Komuro and Hirata, {Ken Ichi} and Koichi Node and Shingo Matsumoto",

note = "Funding Information: I. Komuro received unrestricted research grants from Daiichi Sankyo Company, Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Ltd., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Ltd., Idorsia Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Ono Pharmaceutical Co., Ltd., and Toa Eiyo Ltd. and lecture fees from AstraZeneka, Daiichi Sankyo Company, Ltd., Takeda Pharmaceutical Company Ltd., Bayer Yakuhin, Ltd., Pfizer Japan Inc., and Ono Pharmaceutical Co., Ltd. Funding Information: S. Kohsaka received unrestricted research grants from the Department of Cardiology, Keio University School of Medicine provided by Daiichi Sankyo Co., Ltd. And Bristol-Meyers Squibb, and lecture fees from AstraZeneka and Bristol-Meyers Squibb. Funding Information: Y. Ikari received lecture fees from Asteras, Amgen Biopharma, AstraZeneca, Sanofi, Daiichi Sankyo, Bayer, and Bristol Myers Squib and research grants from Boston Scientific, Daiichi Sankyo, and Japan Mediphysics, and royalty from Terumo. Funding Information: The authors would like to acknowledge all the investigators participating in the CLAVIS-COVID and the Japanese Circulation Society. Publisher Copyright: {\textcopyright} All rights are reserved to the Japanese Circulation Society.",

year = "2021",

doi = "10.1253/circj.CJ-21-0087",

language = "English",

volume = "85",

pages = "939--943",

journal = "Circulation Journal",

issn = "1346-9843",

publisher = "Japanese Circulation Society",

number = "6",

}

TY - JOUR

T1 - Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors

AU - Ikari, Yuji

AU - Matsue, Yuya

AU - Torii, Sho

AU - Hasegawa, Misaki

AU - Aihara, Kazuki

AU - Kuroda, Shunsuke

AU - Sano, Takahide

AU - Kitai, Takeshi

AU - Yonetsu, Taishi

AU - Kohsaka, Shun

AU - Kishi, Takuya

AU - Komuro, Issei

AU - Hirata, Ken Ichi

AU - Node, Koichi

AU - Matsumoto, Shingo

N1 - Funding Information: I. Komuro received unrestricted research grants from Daiichi Sankyo Company, Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Ltd., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Ltd., Idorsia Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Ono Pharmaceutical Co., Ltd., and Toa Eiyo Ltd. and lecture fees from AstraZeneka, Daiichi Sankyo Company, Ltd., Takeda Pharmaceutical Company Ltd., Bayer Yakuhin, Ltd., Pfizer Japan Inc., and Ono Pharmaceutical Co., Ltd. Funding Information: S. Kohsaka received unrestricted research grants from the Department of Cardiology, Keio University School of Medicine provided by Daiichi Sankyo Co., Ltd. And Bristol-Meyers Squibb, and lecture fees from AstraZeneka and Bristol-Meyers Squibb. Funding Information: Y. Ikari received lecture fees from Asteras, Amgen Biopharma, AstraZeneca, Sanofi, Daiichi Sankyo, Bayer, and Bristol Myers Squib and research grants from Boston Scientific, Daiichi Sankyo, and Japan Mediphysics, and royalty from Terumo. Funding Information: The authors would like to acknowledge all the investigators participating in the CLAVIS-COVID and the Japanese Circulation Society. Publisher Copyright: © All rights are reserved to the Japanese Circulation Society.

PY - 2021

Y1 - 2021

N2 - Background: Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19). Methods and Results: In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus. Conclusions: This study suggests the potential benefits of statins use against COVID-19.

AB - Background: Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19). Methods and Results: In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus. Conclusions: This study suggests the potential benefits of statins use against COVID-19.

KW - Cardiovascular risk factors

KW - Coronavirus disease 2019 (COVID-19)

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=85107084843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107084843&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-21-0087

DO - 10.1253/circj.CJ-21-0087

M3 - Article

C2 - 33952833

AN - SCOPUS:85107084843

VL - 85

SP - 939

EP - 943

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 6

ER -

Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this